Poiesis Therapeutics Inc
We are focused on developing a novel therapeutic to maintain remission status in pets with cancer.
- Stage Product In Development
- Industry Biotechnology
- Location San Diego, CA, US
- Currency USD
- Founded September 2015
- Employees 2
- Incorporation Type C-corp
- Website poiesistherapeutics.com
Company Summary
Poïesis Therapeutics Inc is a pet health biotechnology start-up focused a novel therapeutic for maintenance of remission in pets with cancer. Cancer is the leading cause of disease-related deaths in dogs and cats. Nearly 50% of all dogs over 10 years-old will develop cancer. We have in-licensed the veterinary rights to a non-toxic peptide which is active against three major pillars of cancer growth: angiogenesis, chemo-resistance and metastasis.
Team
-
President and Chief Executive OfficerJessica is an equine veterinarian with 22 years of practice experience and has owned and managed a large practice since 1996. She holds a Doctor of Veterinary Medicine degree from the University of California at Davis and an MBA from London Business School.
-
Chief Business Officer and Co-FounderRichard has more than 25 years of biotechnology industry experience in the US and Europe. He has deep business development experience, recently as the Chief Business Officer at Cytheris SA (Paris) and prior to that as Managing Director and VP of BioAlliance Pharma (Paris). While at BioAlliance (now Onxeo), he led the company’s oversubscribed IPO on NYSE Euronext. He holds degrees from University of California at Berkeley and Harvard University.
Advisors
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.